

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Armistead et al.

Serial No.:

09/685,053

Group Art Unit: 1624

Filed:

October 6, 2000

Examiner:

V. Balasubramanian

For:

KINASE INHIBITORS

Docket No.:

A-748E

## AMENDMENT AND RESPONSE

The Commissioner of Patents and Trademarks Washington, D.C. 20231

Dear Sir:

In response to the Office Action dated December 17, 2001, rejecting Claims 1-31 of the above-identified application, reconsideration and withdrawal of the outstanding rejections are respectfully requested. Applicants amend the subject application as follows:

## In the Claims

Cancel claims 30-31, without prejudice.

Amend Claims 1-29, as follows:

1. A compound having the formula:

wherein,

Each R<sup>1</sup> and R<sup>2</sup> is independently R<sup>3</sup>; R<sup>8</sup>; NHR<sup>3</sup>; NHR<sup>5</sup>; NHR<sup>6</sup>; NR<sup>5</sup>R<sup>5</sup>; NR<sup>5</sup>R<sup>6</sup>; SR<sup>5</sup>; SR<sup>6</sup>; SR<sup>6</sup>; SR<sup>3</sup>; OR<sup>5</sup>; OR<sup>6</sup>; OR<sup>3</sup>; C(O)R<sup>3</sup>; heterocyclyl optionally substituted with 1-4 independent R<sup>4</sup> on each ring; or C1-C10 alkyl substituted with 1-4 independent R<sup>4</sup>;